Charlottetown PEI. February 24, 2012 CNS|CRO is pleased to announce that pre-clinical work,using stroke model technology now exclusively licensed to CNS|CRO, had promoted the test compound NA1 directly from rodent testing to successful Phase I through IIA trials. Now a successful Phase IIB trial has been concluded by NoNO Inc. demonstrating clinical efficacy in the ENACT trial for embolic stroke. Topline results from the clinical trial were presented at the recent International Stroke Conference in New Orleans. Full results are expected to be published in a leading peer-reviewed journal and should appear in print in the summer of 2012. For further information, please watch an interview with the trial principal investigator, Dr. Michael D. Hill.
Mr. Kenneth Cawkell, President, CEO and Chairman said “these are the most advanced clinical results providing further validation of the predictive power of the stroke model technology offered by CNS|CRO.”. Dr. Andrew Tasker, PhD FCAHS, Professor of Neuropharmacology at the Atlantic Veterinary College, UPEI who led the team that developed this novel technology said, “this is the first experimental stroke treatment to demonstrate neuroprotection in man, it is very rewarding to have our work contribute to this potential therapeutic for such an important condition.”.
CNS Contract Research Corporation (CNS|CRO) is a private pre-clinical neurological disease specialty laboratory located in Charlottetown PE. It maintains close affiliations with one of the leading veterinary schools in Canada, the Atlantic Veterinary College. CNS offers a range of proprietary animal models for pre-clinical evaluation of test compounds for neurodegenerative
disease. Proprietary disease models include Parkinson’s disease, ALS, Epilepsy, Schizophrenia and a range of Stroke models. CNS has extensive expertise in neuro-behavioural assessment and offers an extensive complement of histopathological services.
For further information contact
W.M. (Bill) Cheliak
bcheliak@cnscro.com
+1.902.442.9185